

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

ELI LILLY AND COMPANY

By Rimdam M. Dublin

Date March 22, 2006

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Richard Dennis DiMarchi, et al.)
Serial No. : 10/516,490)
International : Confirmation No.: 8626)
Application Date : June 2, 2003)
For : Modified Glucagon-Like Peptide-1 Analogs)
Docket No. : X-15642)


STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 C.F.R. 1.821(f) (SEQUENCE LISTING)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby affirm that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. 1.821(c) and (e), respectively, are the same.

Respectfully submitted,


Alejandro Martinez
Agent for Applicants
Registration No. 58,163
Phone: 317-277-4260

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

March 22, 2006



STIC Biotechnology Systems Branch

RAW SEQUENCE LISTING
ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 10/516,490A
Source: PCF/10
Date Processed by STIC: 1/16/06

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.2.2 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm>


Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<http://www.uspto.gov/ebs/efs/downloads/documents.htm>) , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05):
U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street, Alexandria, VA 22314

Revised 01/24/05



PCT

RAW SEQUENCE LISTING

DATE: 01/10/2006

PATENT APPLICATION: US/10/516,490A

TIME: 08:39:08

Input Set : A:\X15642.Nat1Phase.ST25.txt

Output Set: N:\CRF4\01102006\J516490A.raw

3 <110> APPLICANT: Richard Dennis DiMarchi
4 David Lee Smiley
5 Lianshan Zhang
7 <120> TITLE OF INVENTION: MODIFIED GLUCAGON-LIKE PEPTIDE-1 ANALOGS
9 <130> FILE REFERENCE: X-15642 National Phase
C--> 11 <140> CURRENT APPLICATION NUMBER: US/10/516,490A
C--> 11 <141> CURRENT FILING DATE: 2004-12-01
11 <160> NUMBER OF SEQ ID NOS: 24
13 <170> SOFTWARE: PatentIn version 3.2
15 <210> SEQ ID NO: 1
16 <211> LENGTH: 31
17 <212> TYPE: PRT
18 <213> ORGANISM: Artificial
20 <220> FEATURE:
21 <223> OTHER INFORMATION: Synthetic constructs
24 <220> FEATURE:
25 <221> NAME/KEY: MISC_FEATURE
26 <222> LOCATION: (1)..(1) ✓
27 <223> OTHER INFORMATION: Xaa= L-histidine, D-histidine, desamino-histidine,
28 2-amino-histidine, beta-hydroxy-
29 histidine, homohistidine, alpha-fluoromethyl-histidine, or alpha
30 methyl-histidine
32 <220> FEATURE:
33 <221> NAME/KEY: MISC_FEATURE
34 <222> LOCATION: (2)..(2) ✓
35 <223> OTHER INFORMATION: Xaa= Ala, Gly, Val, Leu, Ile, Ser, or Thr
37 <220> FEATURE:
38 <221> NAME/KEY: MISC_FEATURE
39 <222> LOCATION: (6)..(6) ✓
40 <223> OTHER INFORMATION: Xaa= Phe, Trp, or Tyr
42 <220> FEATURE:
43 <221> NAME/KEY: MISC_FEATURE
44 <222> LOCATION: (10)..(10) ✓
45 <223> OTHER INFORMATION: Xaa= Val, Trp, Ile, Leu, Phe, or Tyr
47 <220> FEATURE:
48 <221> NAME/KEY: MISC_FEATURE
49 <222> LOCATION: (12)..(12)
50 <223> OTHER INFORMATION: Xaa= Ser, Trp, Tyr, Phe, Lys, Ile, Leu, Val
52 <220> FEATURE:
53 <221> NAME/KEY: MISC_FEATURE
54 <222> LOCATION: (13)..(13)
55 <223> OTHER INFORMATION: Xaa= Tyr, Trp, or Phe
57 <220> FEATURE:

2-3,5-7
**Does Not Comply
Corrected Diskette Needed**

RAW SEQUENCE LISTING

DATE: 01/10/2006

PATENT APPLICATION: US/10/516,490A

TIME: 08:39:08

Input Set : A:\X15642.NatlPhase.ST25.txt

Output Set: N:\CRF4\01102006\J516490A.raw

```

58 <221> NAME/KEY: MISC_FEATURE
59 <222> LOCATION: (14)..(14)
60 <223> OTHER INFORMATION: Xaa= Leu, Phe, Tyr, or Trp
62 <220> FEATURE:
63 <221> NAME/KEY: MISC_FEATURE
64 <222> LOCATION: (16)..(16)
65 <223> OTHER INFORMATION: Xaa= Gly, Glu, Asp, Lys
67 <220> FEATURE:
68 <221> NAME/KEY: MISC_FEATURE
69 <222> LOCATION: (19)..(19)
70 <223> OTHER INFORMATION: Xaa= Ala, Val, Ile, or Leu
72 <220> FEATURE:
73 <221> NAME/KEY: MISC_FEATURE
74 <222> LOCATION: (21)..(21)
75 <223> OTHER INFORMATION: Xaa= Glu, Ile, or Ala
77 <220> FEATURE:
78 <221> NAME/KEY: MISC_FEATURE
79 <222> LOCATION: (24)..(24)
80 <223> OTHER INFORMATION: Xaa= Ala, or Glu
82 <220> FEATURE:
83 <221> NAME/KEY: MISC_FEATURE
84 <222> LOCATION: (27)..(27)
85 <223> OTHER INFORMATION: Xaa= Val, or Ile
87 <220> FEATURE:
88 <221> NAME/KEY: MISC_FEATURE
89 <222> LOCATION: (31)..(31)
90 <223> OTHER INFORMATION: Xaa= L-Cys, D-Cys, homocysteine, or penicillamine
92 <400> SEQUENCE: 1
W--> 94 Xaa Xaa Glu Gly Thr Xaa Thr Ser Asp Xaa Ser Xaa Xaa Xaa Glu Xaa
      95 1             5             10             15
W--> 98 Gln Ala Xaa Lys Xaa Phe Ile Xaa Trp Leu Xaa Lys Gly Arg Xaa
      99             20             25             30
102 <210> SEQ ID NO: 2
103 <211> LENGTH: 31
104 <212> TYPE: PRT
105 <213> ORGANISM: Artificial
107 <220> FEATURE:
108 <223> OTHER INFORMATION: Synthetic construct
111 <220> FEATURE:
112 <221> NAME/KEY: MISC_FEATURE
113 <222> LOCATION: (1)..(1)
114 <223> OTHER INFORMATION: Xaa= L-histidine, D-histidine, desamino-
histidine,
115      2-amino-histidine, beta-hydroxy-
116      histidine, homohistidine, alpha-fluoromethyl-histidine, or
117      alpha-methyl-histidine
119 <220> FEATURE:
120 <221> NAME/KEY: MISC_FEATURE
121 <222> LOCATION: (2)..(2)
122 <223> OTHER INFORMATION: Xaa= Gly, Ala, Val, Leu, Ile, Ser or Thr

```

RAW SEQUENCE LISTING

DATE: 01/10/2006

PATENT APPLICATION: US/10/516,490A

TIME: 08:39:08

Input Set : A:\X15642.NatlPhase.ST25.txt

Output Set: N:\CRF4\01102006\J516490A.raw

124 <220> FEATURE:
 125 <221> NAME/KEY: MISC_FEATURE
 126 <222> LOCATION: (10)..(10)
 127 <223> OTHER INFORMATION: Xaa = Val, Phe, Tyr, or Trp
 129 <220> FEATURE:
 130 <221> NAME/KEY: MISC_FEATURE
 131 <222> LOCATION: (12)..(12)
 132 <223> OTHER INFORMATION: Xaa = Ser, Tyr, Trp, Phe, Lys, Ile, Leu, or Val
 134 <220> FEATURE:
 135 <221> NAME/KEY: MISC_FEATURE
 136 <222> LOCATION: (16)..(16)
 137 <223> OTHER INFORMATION: Xaa = Gly, Clu Asp, or Lys *do you mean Glu?*
 139 <220> FEATURE:
 140 <221> NAME/KEY: MISC_FEATURE
 141 <222> LOCATION: (19)..(19)
 142 <223> OTHER INFORMATION: Xaa = Ala, Val, Ile, or Leu
 144 <220> FEATURE:
 145 <221> NAME/KEY: MISC_FEATURE
 146 <222> LOCATION: (27)..(27)
 147 <223> OTHER INFORMATION: Xaa = Val or Ile
 149 <220> FEATURE:
 150 <221> NAME/KEY: MISC_FEATURE
 151 <222> LOCATION: (31)..(31)
 152 <223> OTHER INFORMATION: Xaa = L-Cys, D-Cys, homocysteine, or
 penicillamine
 154 <400> SEQUENCE: 2
 W--> 156 Xaa Xaa Glu Gly Thr Phe Thr Ser Asp Xaa Ser Xaa Tyr Leu Glu Xaa
 157 1 5 10 15
 W--> 160 Gln Ala Xaa Lys Glu Phe Ile Ala Trp Leu Xaa Lys Gly Arg Xaa
 161 20 25 30
 164 <210> SEQ ID NO: 3
 165 <211> LENGTH: 42
 166 <212> TYPE: PRT
 167 <213> ORGANISM: Artificial
 169 <220> FEATURE:
 170 <223> OTHER INFORMATION: Synthetic construct
 173 <220> FEATURE:
 174 <221> NAME/KEY: MISC_FEATURE
 175 <222> LOCATION: (1)..(1)
 176 <223> OTHER INFORMATION: Xaa = L-histidine, D-histidine, desamino-
 histidine,
 177 2-amino-histidine, beta-hydroxy-
 178 histidine, homohistidine, alpha-fluoromethyl-histidine, or
 179 alpha-methyl-histidine
 181 <220> FEATURE:
 182 <221> NAME/KEY: MISC_FEATURE
 183 <222> LOCATION: (2)..(2)
 184 <223> OTHER INFORMATION: Xaa = Ala, Gly, Val, Leu, Ile, Ser, or Thr
 186 <220> FEATURE:
 187 <221> NAME/KEY: MISC_FEATURE
 188 <222> LOCATION: (6)..(6)

RAW SEQUENCE LISTING

DATE: 01/10/2006

PATENT APPLICATION: US/10/516,490A

TIME: 08:39:08

Input Set : A:\X15642.NatlPhase.ST25.txt

Output Set: N:\CRF4\01102006\J516490A.raw

189 <223> OTHER INFORMATION: Xaa = Phe, Trp, or Tyr
191 <220> FEATURE:
192 <221> NAME/KEY: MISC_FEATURE
193 <222> LOCATION: (10)..(10)
194 <223> OTHER INFORMATION: Xaa = Val, Trp, Ile, Leu, Phe, or Tyr
196 <220> FEATURE:
197 <221> NAME/KEY: MISC_FEATURE
198 <222> LOCATION: (12)..(12)
199 <223> OTHER INFORMATION: Xaa = Ser, Trp, Tyr, Phe, Lys, Ile, Leu, Val
201 <220> FEATURE:
202 <221> NAME/KEY: MISC_FEATURE
203 <222> LOCATION: (13)..(13)
204 <223> OTHER INFORMATION: Xaa = Tyr, Trp, or Phe
206 <220> FEATURE:
207 <221> NAME/KEY: MISC_FEATURE
208 <222> LOCATION: (14)..(14)
209 <223> OTHER INFORMATION: Xaa = Leu, Phe, Tyr, or Trp
211 <220> FEATURE:
212 <221> NAME/KEY: MISC_FEATURE
213 <222> LOCATION: (16)..(16)
214 <223> OTHER INFORMATION: Xaa = Gly, Glu, Asp, or Lys
216 <220> FEATURE:
217 <221> NAME/KEY: MISC_FEATURE
218 <222> LOCATION: (19)..(19)
219 <223> OTHER INFORMATION: Xaa = Ala, Val, Ile, or Leu
221 <220> FEATURE:
222 <221> NAME/KEY: MISC_FEATURE
223 <222> LOCATION: (21)..(21)
224 <223> OTHER INFORMATION: Xaa = Glu, Ile, or Ala
226 <220> FEATURE:
227 <221> NAME/KEY: MISC_FEATURE
228 <222> LOCATION: (24)..(24)
229 <223> OTHER INFORMATION: Xaa = Ala or Glu
231 <220> FEATURE:
232 <221> NAME/KEY: MISC_FEATURE
233 <222> LOCATION: (27)..(27)
234 <223> OTHER INFORMATION: Xaa = Val or Ile
236 <220> FEATURE:
237 <221> NAME/KEY: MISC_FEATURE
238 <222> LOCATION: (28)..(28)
239 <223> OTHER INFORMATION: Xaa = Lys, Asp, Arg, or Glu
241 <220> FEATURE:
242 <221> NAME/KEY: MISC_FEATURE
243 <222> LOCATION: (30)..(30)
244 <223> OTHER INFORMATION: Xaa = Gly, Pro, or Arg
246 <220> FEATURE:
247 <221> NAME/KEY: MISC_FEATURE
248 <222> LOCATION: (31)..(31)
249 <223> OTHER INFORMATION: Xaa = Gly, Pro, Ser, L-Cys, D-Cys, homocysteine,
or penicillamine

RAW SEQUENCE LISTING

DATE: 01/10/2006

PATENT APPLICATION: US/10/516,490A

TIME: 08:39:08

Input Set : A:\X15642.NatlPhase.ST25.txt

Output Set: N:\CRF4\01102006\J516490A.raw

251 <220> FEATURE:
 252 <221> NAME/KEY: MISC_FEATURE
 253 <222> LOCATION: (32)..(32)
 254 <223> OTHER INFORMATION: Xaa = Ser, Pro, His, L-Cys, D-Cys, homocysteine,
 penicillamine, NH2 *do you mean "amidation"? If so, please add "amidated" to "NH2"*
 255
 257 <220> FEATURE:
 258 <221> NAME/KEY: MISC_FEATURE
 259 <222> LOCATION: (33)..(33)
 260 <223> OTHER INFORMATION: Xaa = Ser, Arg, Thr, Trp, Lys, L-Cys, D-Cys,
 homocysteine,
 261 penicillamine, NH2 or
 262 is absent
 264 <220> FEATURE:
 265 <221> NAME/KEY: MISC_FEATURE
 266 <222> LOCATION: (34)..(34)
 267 <223> OTHER INFORMATION: Xaa = Ser, Gly, L-Cys, D-Cys, homocysteine,
 penicillamine, NH2,
 268 or is absent
 270 <220> FEATURE:
 271 <221> NAME/KEY: MISC_FEATURE
 272 <222> LOCATION: (35)..(35)
 273 <223> OTHER INFORMATION: Xaa = Ala, Asp, Arg, Glu, Lys, Gly, L-Cys, D-Cys,
 homocysteine,
 274 penicillamine,
 275 NH2 or is absent
 277 <220> FEATURE:
 278 <221> NAME/KEY: MISC_FEATURE
 279 <222> LOCATION: (36)..(36)
 280 <223> OTHER INFORMATION: Xaa = Pro, Ala, L-Cys, D-Cys, homocysteine,
 penicillamine, NH2,
 281 or is absent
 283 <220> FEATURE:
 284 <221> NAME/KEY: MISC_FEATURE
 285 <222> LOCATION: (37)..(37)
 286 <223> OTHER INFORMATION: Xaa = Pro, Ala, L-Cys, D-Cys, homocysteine,
 penicillamine, NH2 or
 287 is absent
 289 <220> FEATURE:
 290 <221> NAME/KEY: MISC_FEATURE
 291 <222> LOCATION: (38)..(38)
 292 <223> OTHER INFORMATION: Xaa = Pro, Ala, Arg, Lys, His, L-Cys, D-Cys, Cys,
 homocysteine,
 293 penicillamine, NH2 or
 294 is absent
 296 <220> FEATURE:
 297 <221> NAME/KEY: MISC_FEATURE
 298 <222> LOCATION: (39)..(39)
 299 <223> OTHER INFORMATION: Xaa = Ser, His, Pro, Lys, Arg, L-Cys, D-Cys,
 homocysteine,
 300 penicillamine, NH2 or
 301 is absent
 303 <220> FEATURE:

304 <221> NAME/KEY: MISC_FEATURE
305 <222> LOCATION: (40)..(40)
306 <223> OTHER INFORMATION: Xaa = His, Ser, Arg, Lys, L-Cys, D-Cys,
homocysteine,
307 penicillamine, NH₂ or

*Please ensure that amino acids are
spelled correctly in subsequent sequences.*

RAW SEQUENCE LISTING ERROR SUMMARY
 PATENT APPLICATION: US/10/516,490A

DATE: 01/10/2006
 TIME: 08:39:09

Input Set : A:\X15642.Nat1Phase.ST25.txt
 Output Set: N:\CRF4\01102006\J516490A.raw

FYI

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220>

to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:1; Xaa Pos. 1, 2, 6, 10, 12, 13, 14, 16, 19, 21, 24, 27, 31
 Seq#:2; Xaa Pos. 1, 2, 10, 12, 16, 19, 27, 31
 Seq#:3; Xaa Pos. 1, 2, 6, 10, 12, 13, 14, 16, 19, 21, 24, 27, 28, 30, 31, 32, 33, 34, 35, 36
 Seq#:3; Xaa Pos. 37, 38, 39, 40, 41, 42
 Seq#:4; Xaa Pos. 1, 2, 10, 16, 19, 27, 28, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42
 Seq#:5; Xaa Pos. 1, 2, 16, 19, 27, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42
 Seq#:6; Xaa Pos. 1, 2, 6, 10, 12, 13, 14, 16, 19, 21, 24, 27, 28, 30, 31, 32, 33, 34, 35, 36
 Seq#:6; Xaa Pos. 37, 38, 39, 40, 41, 42, 43, 44, 45
 Seq#:7; Xaa Pos. 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45
 Seq#:8; Xaa Pos. 1, 2, 6, 10, 12, 13, 14, 16, 19, 21, 24, 27
 Seq#:9; Xaa Pos. 1, 2, 10, 12, 16, 19, 27
 Seq#:10; Xaa Pos. 1, 2, 6, 10, 12, 13, 14, 16, 19, 21, 24, 27, 28, 30, 31, 32, 33, 34, 35, 36
 Seq#:10; Xaa Pos. 37, 38, 39, 40, 41, 42
 Seq#:11; Xaa Pos. 1, 2, 10, 16, 19, 27, 28, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42
 Seq#:12; Xaa Pos. 1, 2, 16, 19, 27, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42
 Seq#:13; Xaa Pos. 1, 2, 6, 10, 12, 13, 14, 16, 19, 21, 24, 27, 28, 30, 31, 32, 33, 34, 35, 36
 Seq#:13; Xaa Pos. 37, 38, 39, 40, 41, 42, 43, 44, 45
 Seq#:14; Xaa Pos. 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45
 Seq#:15; Xaa Pos. 1, 2, 6, 10, 12, 13, 14, 16, 19, 21, 24, 27, 31

Invalid <213> Response:

Use of "Artificial" only as "<213> Organism" response is incomplete, per 1.823(b) of New Sequence Rules. Valid response is Artificial Sequence.

Seq#:1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22

VERIFICATION SUMMARY

DATE: 01/10/2006

PATENT APPLICATION: US/10/516,490A

TIME: 08:39:09

Input Set : A:\X15642.NatlPhase.ST25.txt

Output Set: N:\CRF4\01102006\J516490A.raw

L:11 M:270 C: Current Application Number differs, Replaced Current Application No
L:11 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:94 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:0
L:98 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:16
L:156 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2 after pos.:0
L:160 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2 after pos.:16
L:324 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3 after pos.:0
L:328 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3 after pos.:16
L:332 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3 after pos.:32
L:466 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4 after pos.:0
L:470 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4 after pos.:16
L:474 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4 after pos.:32
L:583 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5 after pos.:0
L:587 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5 after pos.:16
L:591 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5 after pos.:32
L:762 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6 after pos.:0
L:766 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6 after pos.:16
L:770 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6 after pos.:32
L:869 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7 after pos.:16
L:873 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7 after pos.:32
L:951 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8 after pos.:0
L:955 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8 after pos.:16
L:1008 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9 after pos.:0
L:1012 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9 after pos.:16
L:1160 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10 after pos.:0
L:1164 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10 after pos.:16
L:1168 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10 after pos.:32
L:1286 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11 after pos.:0
L:1290 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11 after pos.:16
L:1294 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11 after pos.:32
L:1391 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:12 after pos.:0
L:1395 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:12 after pos.:16
L:1399 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:12 after pos.:32
L:1561 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:13 after pos.:0
L:1565 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:13 after pos.:16
L:1569 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:13 after pos.:32
L:1658 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:14 after pos.:16
L:1662 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:14 after pos.:32
L:1745 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:15 after pos.:0
L:1749 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:15 after pos.:16